Fernando is a Process Manufacturing Engineer at Stratasys Direct, where he focuses on advancing additive manufacturing for real-world production. With expertise in SLA and P3™ DLP technologies, he works to optimize and validate processes for high-performance applications, particularly in regulated industries. His work includes material validation, process development, and scaling production to support customers in the medical sector and other highly regulated environments. Fernando holds a degree in Mechanical Engineering from Northern Arizona University and is focused on translating advanced additive manufacturing capabilities into reliable, production-ready solutions.
Medical additive manufacturing (AM) is reshaping how devices are designed, developed, and delivered to patients. From patient-specific implants to surgical planning models, the ability to produce complex, customized parts has opened new possibilities across healthcare.
But innovation alone is not enough. In medical applications, every part must meet strict regulatory requirements and, most importantly, ensure patient safety. That means success in medical AM depends on far more than printing capability—it requires validated processes, controlled workflows, and deep regulatory understanding.
Organizations exploring Stratasys Direct’s medical additive manufacturing solutions must take an integrated approach that integrates design, materials, post-processing, and compliance from the very beginning.
In most industries, performance and cost are the primary drivers. In medical manufacturing, patient safety and satisfaction are the foundations of every decision. Devices often come into direct or indirect contact with the human body, meaning even small inconsistencies can carry serious consequences.
This shifts the mindset entirely. Design decisions are no longer based solely on functionality—they must also account for biological response, sterilization compatibility, and long-term performance. From concept through validation, every step must demonstrate that the device is safe for its intended use.
Additive manufacturing has found strong adoption across several key medical applications. These include orthopedic implants, surgical devices, surgical guides, anatomical models, and prosthetics.
What connects these use cases is the need for customization and complexity. Whether it’s matching a patient’s anatomy or producing intricate geometries that improve performance, AM enables solutions that traditional manufacturing cannot easily achieve.
Unlike conventional methods that often require tooling, molds, or extensive setup, additive manufacturing enables rapid iteration and direct production from digital designs. This significantly reduces lead times, enabling the delivery of patient-specific or highly complex parts much faster than traditional manufacturing approaches.
For a broader look at how these applications are evolving, users can explore medical additive manufacturing solutions on the main industry page.
Biocompatibility is one of the most critical—and often misunderstood—concepts in medical manufacturing. At its core, it means that a device can perform its intended function without causing harmful biological effects under real-world conditions.
However, this definition goes beyond simply selecting a “biocompatible” material.
A key challenge in additive manufacturing is that the final part is not identical to the raw material. The printing process, thermal exposure, surface finishing, and cleaning steps all influence the final chemistry and structure of the device.
As a result, regulatory bodies evaluate the finished device, not just the starting material. A material that is safe in one workflow may not be safe in another if processing conditions change.
This is why companies must think in terms of a validated system, not isolated inputs.
Biocompatibility is established through a risk-based evaluation strategy that considers the nature and duration of a device’s interaction with the body. This approach is guided by ISO 10993, which provides a framework for determining appropriate biological endpoints and testing requirements.
While specific requirements vary by application, evaluations commonly include:
The final selection of tests depends on factors such as contact duration, tissue type, and device classification, underscoring the importance of early planning and alignment with regulatory expectations.
One of the most common mistakes in medical AM is treating sterilization as something that happens at the end of production. In reality, sterilization should be considered at the concept stage.
Additive manufacturing enables highly complex geometries—internal channels, lattice structures, and porous surfaces. While these features can improve performance, they can also create areas where contaminants are difficult to remove or where sterilization agents cannot effectively penetrate.
Sterilization methods themselves can significantly impact material performance. Some materials may not withstand certain sterilization processes, leading to warping, degradation, or changes in mechanical properties. As a result, material compatibility with the intended sterilization method must be evaluated early to avoid downstream issues.
Designing without sterilization in mind can lead to costly redesigns or failed validation later.
Two of the most frequent issues seen in medical AM are material degradation and incomplete sterilization. Complex geometries can prevent sterilants from reaching all surfaces, while certain materials may weaken or fail after repeated sterilization cycles.
These challenges reinforce the importance of aligning design, material, and process decisions early in development.
Different sterilization methods interact with materials in very different ways, and these effects must be accounted for during material selection and validation.
Selecting the wrong method or failing to validate compatibility can compromise both performance and safety.
Certification readiness is not a single milestone—it is the result of a fully developed and validated system. This includes both the product design and the manufacturing process, each supported by documented evidence that demonstrates safety and repeatability.
In additive manufacturing, this often requires additional scrutiny due to process variability.
To achieve regulatory approval, manufacturers must provide comprehensive documentation that proves the device is safe and consistently produced. This typically includes design controls, risk analysis, process validation, and performance testing.
These elements work together to form a complete picture of how the device is designed, manufactured, and verified.
One of the defining characteristics of medical manufacturing is that approvals apply to both the product and the process. Any change—whether to materials, parameters, or post-processing—must be evaluated for its impact on safety and performance.
In some cases, even small changes can trigger revalidation or require additional regulatory submissions.
Traceability is a cornerstone of medical manufacturing. It allows manufacturers to reconstruct exactly how a device was produced, including the materials, equipment, and processes involved.
This level of visibility is critical not only for compliance, but also for identifying and addressing potential risks to patients.
To support traceability, manufacturers must capture detailed production data. This includes machine information, material lot tracking, process parameters, and inspection results.
Maintaining this data ensures that every part can be linked back to its manufacturing history.
Consistency in additive manufacturing is achieved through strict process control. By locking critical parameters and validating workflows, manufacturers can ensure repeatable results across builds and production lots.
A robust quality management system ties all of these elements together, enabling reliable and compliant production.
One of the most common pitfalls is underestimating the importance of post-processing. Printing is only one step in the overall workflow, and finishing operations such as cleaning and curing, often have the greatest impact on the final part.
These steps must be controlled and validated just as rigorously as the printing process itself.
While additive manufacturing enables complex designs, increased complexity often introduces trade-offs. Inspection becomes more difficult, support structures may require additional labor, and validation becomes more challenging.
Another common misconception is that additive manufacturing simplifies regulatory pathways. In reality, it often introduces additional scrutiny due to the number of variables involved in the process.
Before producing parts, organizations should map out the entire workflow—from design through post-processing—and identify where validation will be required. This proactive approach helps avoid costly delays later.
For many companies, partnering with an experienced provider is the most effective way to navigate the complexities of medical AM. Key considerations include certification, traceability systems, and process validation capabilities.
Medical additive manufacturing offers significant advantages in customization, speed, and design flexibility. However, these benefits can only be realized when supported by rigorous validation, quality systems, and regulatory alignment.
Organizations that approach AM with a systems-level mindset—integrating design, materials, sterilization, and compliance—will be best positioned to scale safely and bring innovative medical devices to market with confidence.
